Lecanemab approval in EU: what should we be ready for?– the EANM perspective
European Journal of Nuclear Medicine and Molecular Imaging · 2025-04 · 52 (5) · 1607-1610
DOI: 10.1007/s00259-025-07066-9 ↗Kurz gefasst
Editorial in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 10.01.2025. Verfasst von Igor Yakushev und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, School of Medicine, TUM University Hospital, Technical University of Munich, Klinikum rechts der Isar Ismaninger Str.…. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technische Universität München.
Abstract (Originalsprache)
copy of the apolipoprotein E ε4 (ApoE ε4) gene, the primary genetic risk factor for sporadic AD. These individuals have a lower incidence of amyloid-related imaging abnormalities (ARIA), a side effect of anti-amyloid antibodies [3], relative
Autor:innen und Institutionen
- Department of Nuclear Medicine, School of Medicine, TUM University Hospital, Technical University of Munich, Klinikum rechts der Isar Ismaninger Str. 22, 81675, Munich, Germany. igor.yakushev@tum.de.
- Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU Nancy, Université de Lorraine, Nancy, France.
- Department of Nuclear Medicine, LMU Hospital, LMU Munich, Munich, Germany.
- Department of Medicine, Unit of Nuclear Medicine, University Hospital of Padova, Padova, Italy.
- CIMUS, Universidade Santiago de Compostela & Nuclear Medicine Department, Univ. Hospital IDIS, Santiago de Compostela, Spain.
- Institute of Nuclear Medicine, University College London, London, UK.
Förderung
- Technische Universität München
Zitieren
APA
Yakushev, I., Verger, A., Brendel, M., Cecchin, D., Fernandez, P. A., Fraioli, F., Grimmer, T., Tolboom, N., Traub-Weidinger, T., Guedj, E., & Van Weehaeghe, D. (2025). Lecanemab approval in EU: what should we be ready for?– the EANM perspective. European Journal of Nuclear Medicine and Molecular Imaging, 52(5), 1607-1610. https://doi.org/10.1007/s00259-025-07066-9
Vancouver
Yakushev I, Verger A, Brendel M, Cecchin D, Fernandez PA, Fraioli F, et al. Lecanemab approval in EU: what should we be ready for?– the EANM perspective. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(5):1607-1610. doi:10.1007/s00259-025-07066-9
BibTeX
@article{Yakushev2025,
author = {Yakushev, Igor and Verger, Antoine and Brendel, Matthias and Cecchin, Diego and Fernandez, Pablo Aguiar and Fraioli, Francesco and Grimmer, Timo and Tolboom, Nelleke and Traub-Weidinger, Tatjana and Guedj, Eric and Van Weehaeghe, Donatienne},
title = {Lecanemab approval in EU: what should we be ready for?– the EANM perspective},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
volume = {52},
number = {5},
pages = {1607--1610},
doi = {10.1007/s00259-025-07066-9}
}
EUVIMED